Cas No.: | 1191265-33-4 |
Chemical Name: | CDDO-dhTFEA |
Synonyms: | CDDO-dhTFEA |
SMILES: | C1(C#N)=C[C@]2(C)[C@@]3([H])CC(=O)[C@]4([H])[C@]5([H])CC(C)(C)CC[C@]5(C(=O)NCC(F)(F)F)CC[C@@]4(C)[C@]3(C)CC[C@@]2([H])C(C)(C)C1=O |
Formula: | C33H45F3N2O3 |
M.Wt: | 574.717220067978 |
Purity: | >98% |
Sotrage: | 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO |
Description: | CDDO-dhTFEA (RTA dh404) is a synthetic oleanane triterpenoid compound which potently activates Nrf2 and inhibits the pro-inflammatory transcription factor NF-κB[1]. CDDO-dhTFEA restores hypertension (MAP), increases Nrf2 and expression of its target genes, attenuates activation of NF-κB and transforming growth factor-β pathways, and reduces glomerulosclerosis, interstitial fibrosis and inflammation in the chronic kidney disease (CKD) rats[2]. |
Target: | NF-κB Nrf2 |
References: | [1]. Aminzadeh MA, et al. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores endothelial function impaired by reduced Nrf2 activity in chronic kidney disease. Redox Biol. 2013 Oct 31;1:527-31. [2]. Aminzadeh MA, et al. The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease. Xenobiotica. 2014 Jun;44(6):570-8. |